

Ref: GLL/BSE/2022/Aug-09

Date: August 31, 2022

To
Corporate Relations Manager
BSE Limited
Phiroje Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

To
Listing Manager
The Ahmedabad Stock Exchange Limited
A-2, Kamdhenu Complex,
Opposite Sahajanand College,
120 Feet Ring Rd, Panjara Pol, Ambawadi,
Ahmedabad – 380 015

To
The Secretary
The Calcutta Stock Exchange Limited
#7, Lyons Range, Murgighata,
Dalhousie, Kolkata – 700 001

Sub: Intimation as per Reg.92 of SEBI (ICDR) Regulations, 2018 and Regulation 30 of SEBI (LODR) Regulations, 2015.

Ref: Proposed Rights Issue of Equity Shares of Gennex Laboratories Limited (the “Company”); BSE Script Code: 531739

Dear Sir/Ma’am,

With reference to captioned subject, this to inform you that the basis of allotment Advertisement dated August 31, 2022 in terms of Regulations 92 of the SEBI (ICDR) Regulations, 2018, as amended, has been published in the following newspaper on Wednesday, August 31, 2022:


1. Financial Express (English) National Daily - All Editions
2. Jansatta (Hindi) National Daily - All Editions
3. Nava Telangana (Telugu) – Hyderabad Editions

We are submitting herewith the newspaper clippings of above mentioned newspapers. We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

For Gennex Laboratories Limited



Rajesh Vankadara
Company Secretary & Compliance Officer
Membership #A44949

Encl: As above

Gennex Laboratories Limited

రిజర్వేషన్లకు బీజేపీ వ్యతిరేకం

ఎంపీ లక్ష్మణ్ వ్యాఖ్యలే సాక్ష్యం: కేపీపీఎస్

నవతెలంగాణ బ్యారో-హైదరాబాద్ సామాజిక వర్గాల రిజర్వేషన్లకు బీజేపీ వ్యతిరేకమని, ఆ పార్టీ ఎంపీ లక్ష్మణ్ వ్యాఖ్యలు ఇదే విషయాన్ని రుజువు చేస్తున్నాయని కుల వివక్ష వ్యతిరేక పోరాట సంఘం(కేపీపీఎస్) రాష్ట్ర అధ్యక్షుడు ప్రధాన కార్యదర్శిలు జానకమ్మ, డి. సైలాబాబు మంగళవారం ఒక ప్రకటనలో తెలిపారు. ఓ పత్రికకు ఇచ్చిన ఇంటర్వ్యూలో లక్ష్మణ్ మాట్లాడుతూ బలహీనవర్గాలకు బీజేపీ ఎంపీ మేలు చేసిందని చెబుతూనే... ఆర్థిక ప్రాతిపదికన రిజర్వేషన్లు ఉండాలంటూ పేర్కొన్నాడని ఖండించారు.

బీజేపీ విఖ్యాత మునుస్వతి వల్లసేపర్తి ఎంపీలు ఎస్పీ, బీసీ తరగతులు సామాజిక, ఆర్థిక, వెనుకబాటుతనాని గుర్తుచేస్తూనే తెలిపారు. ఇలాంటి స్థితిని యధాతథంగా కొనసాగించేందుకే ఆ పార్టీ భావిస్తున్నదని విమర్శించారు. అసమానతలకు కులవ్యవస్థ బలమైన కారణమని తెలిపారు. పుట్టుకతోనే బీజేపీ రిజర్వేషన్ల వ్యతిరేక స్వభావాన్ని కలిగి ఉన్నదని ఆరోపించారు. దాని అధినేతలైన మోడీ, అమిత్ షా, నంద్రా కూడా రిజర్వేషన్ల పట్ల తమ వైఖరి ఇదేనంటూ ఆధికారిక ప్రకటన చేయాలని వద్దెవా చేశారు.

గణేశ్ ఉత్సవాలపై అప్రమత్తంగా ఉండండి

నవతెలంగాణ-ప్రత్యేక ప్రకటన: రాష్ట్రంలో బుధవారం సుందరి భారీ ఉత్సవాలకు నవరాత్రి ఉత్సవాల ప్రారంభమవుతున్న సందర్భంలో ఎలాంటి అవాంఛనీయ సంఘటనలు జరగకుండా పోలీసు యంత్రాంగం అప్రమత్తంగా మెలగాలని రాష్ట్ర డిప్యూటీ ఎం. మహేందర్ రెడ్డి అభిప్రాయం. ఈ సందర్భంగా హైదరాబాద్, నైరాబాద్, రాజ్ కండ పోలీసు కమిషన్లరద్దెలో పాటు జత జిల్లాల కమిషన్లకు, ఎస్పీలకు అయిన తగిన అదేశాలు జారీ చేశారు. టోపింగ్ రోజుల పాటు జరిగే నవరాత్రి ఉత్సవాల సందర్భంగా

ప్రతి గణేశ్ మండపం వద్ద తగిన నిఘాను ఏర్పాటు చేయాలని సీనియర్ పోలీసు అధికారి ప్రకటించిన సందర్భంగా అయిన కోరారు. ముఖ్యంగా, మతపరంగా సున్నిత ప్రాంతాల్లో ప్రత్యేకంగా నిఘా వేసి ఉంచాలని అయిన అభిప్రాయం. అసాంఘిక శక్తులు, రాజీల కరుణలపై కన్నీటి ఉంచాలని అసభ్యులను ఆరోపించారు. జిల్లాల నగరంలో మూసావర్ పాఠశాల, ఎమ్మెల్యే

నగర సీపీలు, జిల్లా ఎస్పీలను ఆదేశించిన డీజీపీ రాజ్ కండ గవీషా వ్యాఖ్యానాలు నగరంలో కాంట్రీబ్యూటర్లకు భారం కలిగించిన సందర్భంలో మరల కట్టుబట్టుతున్న భారత ప్రభుత్వం చేయాలని అయిన అభిప్రాయం. మతులమైన వివాదాలకు ఎవరైనా భంగం వాటిల్లాలా చేసినా వారిపై వెంటనే చట్టరీత్యా చర్యలు తీసుకోవాలని, ఎంట్రీవాలెన్సా డిప్యూటీవారిని అధికారులకు సూచించారు.

This is only an advertisement for information purposes and not for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States. All capitalized terms used and not defined herein shall have the meaning assigned to them in the Letter of Offer dated 16th July, 2022 (Letter of Offer or the LoF) filed with stock exchanges namely BSE Limited (BSE), the Stock Exchange and submitted to the Securities Exchange Board of India (SEBI).



GENNEX LABORATORIES LIMITED

The Company was originally incorporated on 25th June, 1985, as "Pharmasia Drugs and Chemicals Private Limited" under the Companies Act, 1956 as a private limited company with the Registrar of Companies, Bengaluru, Karnataka. The Registered Office of the Company was shifted from the state of Karnataka to Andhra Pradesh on 29th March, 1990 and subsequently the Company was converted into a public limited company on 15th February, 1995. The Company's name was changed to "Prudential Pharmaceuticals Limited" on 22nd February, 1995 and further to "Gennex Laboratories Limited" on 19th September, 2007.

Corporate Identification Number: L24230TG1990PLC011168 Registered Office: Survey #133, IDA Bollaram, Jinnaram Mandal, Sangra Reddy District - 502 325, Telangana, India. Corporate Office: Akash Ganga, 03rd Floor, Plot No.144, Srinagar Colony, Hyderabad 500073, Telangana, India. Phone: 040-67334400; E-mail: investorrelations@gennexlab.com; website: www.gennexlab.com Contact Person: Mr. Rajesh Vankadara, Company Secretary and Compliance Officer

PROMOTERS OF THE COMPANY: MR. ARIHANT BAID AND M/S. PREMIER FISCAL SERVICES PRIVATE LIMITED FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF THE COMPANY ONLY

ISSUE OF UPTO 6,32,51,500 EQUITY SHARES OF FACE VALUE OF ₹1.00 EACH ("RIGHTS EQUITY SHARES") OF THE COMPANY FOR CASH AT A PRICE OF ₹6 PER RIGHTS EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹5 PER RIGHTS EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING UPTO ₹37.951 CRORES ("THE ISSUE") ON A RIGHTS BASIS TO THE EXISTING ELIGIBLE EQUITY SHAREHOLDERS OF THE COMPANY IN THE RATIO OF 1 (ONE) RIGHTS EQUITY SHARE FOR EVERY 2(TWO) FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS 22ND JULY, 2022 (THE "ISSUE"). THE ISSUE PRICE IS FOR THE RIGHTS EQUITY SHARES IS 6 TIMES THE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE REFER TO THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE NO.179 OF THE LETTER OF OFFER.

BASIS OF ALLOTMENT

The Board of Directors of the Gennex Laboratories Limited thanks all investors for their response to the Issue, which opened for subscription on Friday, August 05, 2022 and closed on Friday, August 19, 2022 and the last date for market renunciation on Friday, August 12, 2022. Out of the total number of 2,417 Applications received for 5,46,21,881 Equity Shares which includes Applications for subscriptions to additional Equity Shares, 530 Applications for 20,02,365 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid applications received were 1,887 for 5,25,06,534 Equity Shares which was 83.01% of the number of Rights Equity Shares offered under the Issue. The Issue was subscribed to the extent of 86.36% of the Issue in terms of the number of Equity Shares applied.

The Basis of Allotment was finalised on 25th August, 2022, in consultation with BSE Limited ("BSE"), the Designated Stock Exchange. The Rights Issue Committee of the Company at its meeting held on 26th August, 2022, pursuant to the authority conferred on the Committee by the Board of Directors of the Company that met on 6th April, 2022, has approved to allot 5,25,06,534 Partly paid up Equity Shares to the successful applicants. All valid Applications have been considered for allotment.

1. The break-up of Applications is given below:

Table with 7 columns: Category, Application Received (Number, %), Rights Equity Shares Applied for (Number, Value, %), Rights Equity Shares Allotted (Number, Value, %). Rows include Eligible Equity Shareholders, Renounees, and Total.

2. Basis of Allotment

Table with 6 columns: Category, No. of Valid Applications Received, No. of Shares under valid Applications, No. of Rights Equity Shares accepted and Allotted against Rights Entitlement (A), No. of Rights Equity Shares accepted and Allotted against Additional Rights Equity Shares applied for (B), Total Rights Equity Shares accepted and Allotted (A+B).

Out of a total of 2,417 Applications received, 530 Applications were rejected on technical grounds.

Intimation for Allotment/refund/rejections: The dispatch of allotment order cum refund intimation and intimation for rejection, as applicable, to the Investors has been completed on Friday, 26th August, 2022. The instructions to (i) Axis Bank Limited ("Banker to the Issue") for processing refund through NACH/NEFT/RTGS/ direct credit for Application made using ASBA facility was given on Saturday, 27th August, 2022 and (ii) SCSBs for unlocking of funds in case of ASBA applicants were given on Friday, 26th August, 2022. The credit of Rights Equity Shares in dematerialised form to respective demat accounts of Allottees was completed on Tuesday, 30th August, 2022. The Rights Equity Shares allotted to resident Eligible Equity Shareholders holding Equity Shares in physical form and who have not provided details of their respective demat accounts, have been credited to the demat suspense account, in accordance with the terms of Letter of Offer. Such Eligible Equity Shareholders are required to send, among other details of their demat account to the Company or the Registrars within six (6) months from the Allotment date, to get the Rights Equity Shares transferred in their demat account. In case non-receipt of demat account, the Company shall conduct a sale of such Rights Equity Shares lying in the demat suspense account on the floor of the Stock Exchange at the prevailing market price and remit the proceeds of such sale (net of brokerage, applicable taxes and administrative and incidental charges) to the bank account mentioned by the resident Eligible Equity Shareholders in their respective Application forms and the form for which the application payment was made. For further details, please refer to "Terms of the Issue - Credit of Rights Entitlements in demat accounts of Eligible Equity Shareholders" on page 194 of the Letter of Offer. Pursuant to the listing and trading approvals granted by BSE, the Rights Equity Shares Allotted in the Issue is expected to commence trading on BSE with effect from 2nd September, 2022. In accordance with SEBI circular dated January 22, 2020 the request for extinguishment of rights entitlement has been sent to NSDL & CDSL on 26th August, 2022.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.

DISCLAIMER CLAUSE OF SEBI: The Draft Letter of Offer was not filed with SEBI in terms of SEBI ICDR Regulations as the size of issue is below ₹ 50 crores. However, the Letter of Offer will be filed with SEBI for information and dissemination.

DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE): IT IS TO BE DISTINCTLY UNDERSTOOD THAT THE PERMISSION GIVEN BY BSE LIMITED SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE LETTER OF OFFER HAS BEEN CLEARED OR APPROVED BY BSE LIMITED, NOR DOES IT CERTIFY THE CORRECTNESS OR COMPLETENESS OF ANY OF THE CONTENTS OF THE LETTER OF OFFER. THE INVESTORS ARE ADVISED TO REFER TO THE LETTER OF OFFER FOR THE FULL TEXT OF THE 'DISCLAIMER CLAUSE OF THE BSE LIMITED' ON PAGE 175 OF THE LETTER OF OFFER.

Table with 3 columns: LEAD MANAGER TO THE ISSUE, REGISTRAR TO THE ISSUE, COMPANY SECRETARY AND COMPLIANCE OFFICER. Includes logos and contact details for Quintessence Enterprises Private Limited, Bigshare Services Private Limited, and Gennex Laboratories Limited.

Investors may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre-Issue/post-Issue related matters such as non-receipt of letter of Allotment, non-credit of Allotted Rights Equity Shares in the respective beneficiary account or non-receipt of Refund Orders and such other matters. All grievances relating to the Issue may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the applicant, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Bank of the SCSB where the CAF, or the plain paper application, if applicable, was submitted by the Investors.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

For Gennex Laboratories Limited On behalf of Board of Directors Sd/ Rajesh Vankadara Company Secretary and Compliance Officer

Disclaimer: The Company has filed the Letter of Offer with BSE and SEBI which is available on www.bseindia.com where the shares of the Company are listed, www.sebi.gov.in and the website of the Lead Manager at www.gennexlab.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on Page 21 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.

The Rights Entitlements and the Issue Shares have not been and will not be registered under the Securities Act, or any U.S. state securities laws and may not be offered, sold, resold or otherwise transferred within the United States of America or the territories or possessions thereof (United States or U.S.) or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the Securities Act). The offering to which the Letter of Offer relates is not, and under no circumstances is to be construed as, an offering of any Issue Shares or Rights Entitlement for sale in the United States or as a solicitation therein of an offer to buy any of the Issue Shares or Rights Entitlement. There is no intention to register any portion of the Issue or any of the securities described herein in the United States or to conduct a public offering of securities in the United States. Accordingly, the Letter of Offer, the Abridged Letter of Offer, the CAF should not be forwarded to or transmitted in or into the United States at any time. In addition, until the expiry of 40 days after the commencement of the Issue, an offer or sale of rights Entitlements or Issue Shares within the United States by a dealer (whether or not it is participating in the Issue) may violate the registration requirements of the Securities Act.

RELIANCE ELAYNS HOMES FINANCE LIMITED advertisement with details on home loans, interest rates, and contact information.

ORCHASP LIMITED advertisement with details on company information, contact details, and website.

28th వార్షిక సర్వేసభ, సమావేశం మరియు ఇ-డి.టి.గి సమాచారం ప్రకటన. Includes details on the 28th Annual General Meeting, agenda, and shareholder instructions.

Chola Finance advertisement for Chola Home Finance Limited, detailing home loan products, interest rates, and contact information.